Cefprozil

Cefprozil
Clinical data
Trade names	Cefzil, Cefproz, others
Other names	Cefproxil
AHFS/Drugs.com	Monograph
MedlinePlus	a698022
License data	US FDA: Cefprozil;
Routes of; administration	Oral
ATC code	J01DC10 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Bioavailability	95%
Protein binding	36%
Elimination half-life	1.3 hours
Identifiers
	IUPAC name 7-[2-amino-2-(4-hydroxyphenyl)-acetyl]amino-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
CAS Number	92665-29-7 ;
PubChem CID	9887643;
DrugBank	DB01150 ;
ChemSpider	8063315 ;
UNII	1M698F4H4E;
KEGG	D07651 ;
ChEBI	CHEBI:3506 ;
ChEMBL	ChEMBL1742 ;
CompTox Dashboard (EPA)	DTXSID10873545 ;
Chemical and physical data
Formula	C18H19N3O5S
Molar mass	389.43 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(/C=C/C)CS[C@@H]1[C@@H]2NC(=O)[C@@H](c3ccc(O)cc3)N)C(=O)O.O;
	InChI InChI=1S/C18H19N3O5S.H2O/c1-2-3-10-8-27-17-13(16(24)21(17)14(10)18(25)26)20-15(23)12(19)9-4-6-11(22)7-5-9;/h2-7,12-13,17,22H,8,19H2,1H3,(H,20,23)(H,25,26);1H2/b3-2-;/t12-,13-,17-;/m1./s1 ; Key:ALYUMNAHLSSTOU-HERYOFLYSA-N ;
	(what is this?) (verify)

Cefprozil is a second-generation cephalosporin antibiotic^[1]. It can be used to treat ear infections, skin infections, and other bacterial infections.^{[citation needed]} It comes as a tablet and as a liquid suspension.

Although there is a widely quoted cross-allergy risk of 10% between cephalosporins and penicillin, an article^[2] has shown no increased risk for cross-allergy for cefprozil and several other second-generation or later cephalosporins.

It was patented in 1983 and approved for medical use in 1992.^[3]

Spectrum of bacterial susceptibility and resistance

Currently bacteria like Enterobacter aerogenes, Morganella morganii and Pseudomonas aeruginosa are resistant to cefprozil, while Salmonella enterica serotype Agona and streptococci are susceptible to cefprozil. Some bacteria like Brucella abortus, Moraxella catarrhalis and Streptococcus pneumoniae have developed resistance towards cefprozil in varying degrees. Detailed minimum inhibition concentration information is given by the Cefprozil Susceptibility and Resistance Data sheet.^[4]

Synthesis

This is not a direct copy of Lednicer book like at first glance, but is sourced from the primary reference material.

Displacement of the allylic chloride in intermediate (1) with triphenylphosphine gives the phosphonium salt (2). This functionality is then converted to its ylide; condensation with acetaldehyde then leads to the vinyl derivative (3); deprotection then gives cefprozil. Semisynthetic oral cephalosporin consisting of ~90:10 Z/E isomeric mixture.

^[9]

Brand names

^[10]

References

^ "Cefzil (cefprozil) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2021-05-12.
^ Pichichero ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients" (PDF). The Journal of Family Practice. 55 (2): 106–12. PMID 16451776. Archived from the original on 2012-09-16. Retrieved 2011-02-26.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
^ "Cefprozil Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.
^ DE 3402642, Hoshi H, et al., issued 1984, assigned to Bristol-Myers
^ US 4520022, Hoshi H, et al., issued 1985, assigned to Bristol-Myers
^ Naito T, Hoshi H, Aburaki S, Abe Y, Okumura J, Tomatsu K, Kawaguchi H (July 1987). "Synthesis and structure-activity relationships of a new oral cephalosporin, BMY-28100 and related compounds". The Journal of Antibiotics. 40 (7): 991–1005. doi:10.7164/antibiotics.40.991. PMID 3624077.
^ US 4727070, Kaplan MA, et al., issued 1988, assigned to Bristol-Myers
^ TOMATSU, Kozo; Ando, Shigeyuki; Masuyoshi, Shinji; Kondo, Shoichiro; Hirano, Minoru; Miyaki, Takeo; Kawaguchi, Hiroshi (1987). "In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin". The Journal of Antibiotics. 40 (8): 1175–1183. doi:10.7164/antibiotics.40.1175. ISSN 0021-8820. PMID 3500158.
^ Albanus, Lennart; Björklund, Nils-Erik; Gustafsson, Börje; Jönsson, Monica (1975). "Forty Days Oral Toxicity of 2,6-cis-Diphenylhexamethylcyclotetrasiloxane (KABI 1774) in Beagle Dogs with Special Reference to Effects on the Male Reproductive System". Acta Pharmacologica et Toxicologica. 36 (Suppl 3): 93–130. doi:10.1111/j.1600-0773.1975.tb03087.x. ISSN 0001-6683. PMID 1080338.

External links

Cefprozil MedlinePlus Drug Information

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

[1] "Cefzil (cefprozil) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 2021-05-12.

[2] Pichichero ME (February 2006). "Cephalosporins can be prescribed safely for penicillin-allergic patients" (PDF). The Journal of Family Practice. 55 (2): 106–12. PMID 16451776. Archived from the original on 2012-09-16. Retrieved 2011-02-26.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.

[4] "Cefprozil Susceptibility and Resistance Data" (PDF). Retrieved 23 July 2013.

[5] DE 3402642, Hoshi H, et al., issued 1984, assigned to Bristol-Myers

[6] US 4520022, Hoshi H, et al., issued 1985, assigned to Bristol-Myers

[7] Naito T, Hoshi H, Aburaki S, Abe Y, Okumura J, Tomatsu K, Kawaguchi H (July 1987). "Synthesis and structure-activity relationships of a new oral cephalosporin, BMY-28100 and related compounds". The Journal of Antibiotics. 40 (7): 991–1005. doi:10.7164/antibiotics.40.991. PMID 3624077.

[8] US 4727070, Kaplan MA, et al., issued 1988, assigned to Bristol-Myers

[TOMATSUAndo1987-9] TOMATSU, Kozo; Ando, Shigeyuki; Masuyoshi, Shinji; Kondo, Shoichiro; Hirano, Minoru; Miyaki, Takeo; Kawaguchi, Hiroshi (1987). "In vitro and in vivo evaluations of BMY-28100, a new oral cephalosporin". The Journal of Antibiotics. 40 (8): 1175–1183. doi:10.7164/antibiotics.40.1175. ISSN 0021-8820. PMID 3500158.

[AlbanusBjörklund2009-10] Albanus, Lennart; Björklund, Nils-Erik; Gustafsson, Börje; Jönsson, Monica (1975). "Forty Days Oral Toxicity of 2,6-cis-Diphenylhexamethylcyclotetrasiloxane (KABI 1774) in Beagle Dogs with Special Reference to Effects on the Male Reproductive System". Acta Pharmacologica et Toxicologica. 36 (Suppl 3): 93–130. doi:10.1111/j.1600-0773.1975.tb03087.x. ISSN 0001-6683. PMID 1080338.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]